基于消斑通脉方抗动脉粥样硬化作用机制的网络药理学分析和体外实验验证

doi:10.13481/j.1671-587X.20240406

Abstract

Abstract:

Objective To preliminarily predict the potential pathways and targets of Xiaoban Tongmai Formula in anti-atherosclerosis （AS） by network pharmacology analysis， and to verify its possible mechanism combined with in vitro cell experiment. Method The databases including Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP）， GeneCards， Swiss Target Prediction， and Uniprot were used to collect the information on active compounds and corresponding targets of Xiaoban Tongmai Formula to construct the “compound-target-disease” network. The potential targets and pathways were predicted by protein-protein interaction （PPI） network， and the intersection targets were subjected to Gene Ontology （GO） functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis.The human aortic vascular smooth muscle cells （HA-VSMCs） were cultured and identified in vitro， and the abnormal proliferation of HA-VSMCs were induced by oxidized low-density lipoprotein（ox-LDL） and identified； MTT method was used to detect the proliferation activities of the HA-VSMCs in various groups after treated with different concentrations of Xiaoban Tongmai Formula；the safety of Xiaoban Tongmai Fang was confirmed. The HA-VSMCs were divided into blank group， model group （the abnormal proliferation of HA-VSMCs was induced）， rosuvastatin group （treated with 4 μmol·L^-1 rosuvastatin after inducing the abnormal proliferation of HA-VSMCs）， and low， medium， and high doses of Xiaoban Tongmai Formula groups （treated with 0.025， 0.050， and 0.100 mg·L^-1 Xiaoban Tongmai Formula after inducing the abnormal proliferation of HA-VSMCs）；enzyme-linked immunosorbent assay （ELISA） was used to detect the levels of monocyte chemotactic protein-1（MCP-1）， interleukin-6（IL-6）， and interleukin-8（IL-8） in supernatant of the HA-VSMCs in various groups； real-time fluorescence quantitative PCR （RT-qPCR） method was used to detect the expression levels of nuclear factor kappa-B（NF-κB） p65 mRNA and fibroblast growth factors 2（FGF2） mRNA in the HA-VSMCs in various groups； Western blotting method was used to detect the expression levels of NF-κB p65 and FGF2 proteins in the HA-VSMCs in various groups. Results Xiaoban Tongmai Formula contained 103 active ingredients that exert anti-AS effect by acting on 189 target genes. The potential targets included IL-6， IL-8， vascular endothelial growth factor A（VEGFA）， nuclear factor kappa B1（NF-κB1）， and RELA （NF-κB p65）. The GO functional analysis and KEGG pathway enrichment analysis results showed that Xiaoban Tongmai Formula exerted anti-AS effects by regulating lipid metabolism， hypoxia-inducible factor-1（HIF-1）， epidermal growth factor（EGF）， phosphatidylinositol 3-kinase（PI3K）/protein kinase B（Akt）， and NF-κB signaling pathways.The cell morphology and immunofluorescence staining results confirmed that the cells were HA-VSMCs. The oil red O staining results showed numerous red lipid droplets， indicating successful modeling. The MTT assay results showed that Xiaoban Tongmai Formula had no significant effect on the proliferation rate of HA-VSMCs within a certain dose range， indicating good safety. The ELISA results showed that compared with model group， the levels of MCP-1 and IL-6 in supernatant of the HA-VSMCs in rosuvastatin group and different doses of Xiaoban Tongmai Formula groups were decreased （P<0.05 or P<0.01）， and the levels of IL-8 in supernatant of the HA-VSMCs in 0.050 and 0.100 mg·L^-1 Xiaoban Tongmai Formula groups were decreased （P<0.01）； compared with rosuvastatin group， the levels of MCP-1 in supernatant of the HA-VSMCs in different doses of Xiaoban Tongmai Formula groups were decreased （P<0.01）， and the levels of IL-8 in supernatant of the HA-VSMCs in 0.050 and 0.100 mg·L^-1 Xiaoban Tongmai Formula groups were decreased （P<0.01）. Compared with model group， the expression levels of NF-κB p65 mRNA in the HA-VSMCs in rosuvastatin group and different doses of Xiaoban Tongmai Formula groups were decreased （P<0.01）， and the expression levels of FGF2 mRNA in the HA-VSMCs in rosuvastatin group and 0.050 and 0.100 mg·L^-1 Xiaoban Tongmai Formula groups were decreased （P<0.01）； compared with rosuvastatin group， the expression levels of NF-κB p65 and FGF2 mRNA in the HA-VSMCs in 0.050 and 0.100 mg·L^-1 Xiaoban Tongmai Formula groups were decreased （P<0.05 or P<0.01）. Compared with model group， the expression levels of NF-κB p65 and FGF2 proteins in the HA-VSMCs in rosuvastatin group and different doses of Xiaoban Tongmai Formula groups were decreased （P<0.01）； compared with rosuvastatin group， the expression levels of NF-κB p65 protein in the HA-VSMCs in 0.050 and 0.100 mg·L^-1 Xiaoban Tongmai Formula groups were decreased （P<0.01）， and the expression level of FGF2 protein in the HA-VSMCs in 0.100 mg·L^-1 Xiaoban Tongmai Formula group was decreased （P<0.01）. Conclusion Xiaoban Tongmai Formula has anti-inflammatory effect， inhibitory effect on the proliferation of HA-VSMCs， and anti-AS effect，and its mechanism may be related to the inactivation of NF-κB/FGF2 pathway.

Key words: Xiaoban Tongmai Formula, Atherosclerosis, Vascular smooth muscle cell, Network pharmacology, Cell proliferation

CLC Number:

R285.5

Shan CAO,Yijia ZHANG,Yang BAI,Fang CHEN,Sha XIE,Qianqian HAN. Network pharmacological analysis and in vitro experimental verification based on anti-atherosclerosis mechanism of Xiaoban Tongmai Formula[J].Journal of Jilin University(Medicine Edition), 2024, 50(4): 925-938.

Figures/Tables 17

Tab.1

Fig. 1

Tab.2

Fig. 2

Fig. 5

Fig. 6

Fig. 7

Fig. 8

Tab.3

Fig. 9

Tab.4

Tab.5

Tab.6

Tab.7

Fig. 10

Tab.8

References 33

1	GROOTAERT M O J， BENNETT M R. Vascular smooth muscle cells in atherosclerosis： time for a reassessment［J］. Cardiovasc Res， 2021， 117（11）： 2326-2339.
2	GUIJARRO C， COSÍN-SALES J. LDL cholesterol and atherosclerosis： the evidence［J］. Clin Investig Arterioscler， 2021， 33（）： 25-32.
3	KATTOOR A J， POTHINENI N V K， PALAGIRI D， et al. Oxidative stress in atherosclerosis［J］. Curr Atheroscler Rep， 2017， 19（11）： 42.
4	DEROISSART J， PORSCH F， KOLLER T， et al. Anti-inflammatory and immunomodulatory therapies in atherosclerosis［J］. Handb Exp Pharmacol， 2022， 270： 359-404.
5	庞树朝，张军平，陈美玲，等. 中医药治疗动脉粥样硬化新进展［J］. 中华中医药杂志， 2017， 32（1）： 214-217.
6	中国医师协会中西医结合分会心血管专业委员会，中中医药学会心血管病分会. 动脉粥样硬化中西医防治专家共识（2021年）［J］. 中国中西医结合杂志， 2022， 42（3）： 287-293.
7	张艺嘉，樊珂，崔小数，等. 中医药治疗动脉粥样硬化临床研究进展［J］. 中医学报， 2020， 35（9）： 1908-1912.
8	吴晶魁，杨乔，李洋洋，等. 水蛭通过p38MAPK信号通路对早期动脉粥样硬化大鼠VSMCs的影响［J］. 中国中药杂志， 2017， 42（16）： 3191-3197.
9	王群，杨关林，贾连群，等. 基于网络药理学探讨何首乌治疗动脉粥样硬化作用机制［J］. 辽宁中医药大学学报， 2019， 21（9）： 136-139.
10	郑云霞，孟萌. 中药丹参治疗冠心病的药理成分及作用分析［J］. 双足与保健， 2018， 27（17）： 190-191.
11	任超，王萍，闫东明，等.三七总皂苷对AS小鼠的治疗作用［J］.中国药理学通报，2018，34（9）：1289-1295.
12	甄庆强，张洁，雷震，等. 瓜蒌皮提取物对同型半胱氨酸诱导动脉粥样硬化的保护作用［J］. 东南大学学报（医学版）， 2018， 37（2）： 239-243.
13	于进.天麻酚性成分抗AS的实验研究［D］.昆明：云南中医药大学，2019.
14	荆文光，符江，刘玉梅，等. 水蛭的化学成分［J］. 中国实验方剂学杂志， 2014， 20（19）： 120-123.
15	李国强，李韵仪，李桃，等. 水蛭的化学成分研究［J］. 天津中医药， 2018， 35（9）： 703-705.
16	许石钟. 水蛭经炮制后的化学成分变化研究［J］. 陕西中医， 2018， 39（7）： 980-982.
17	朱迪，曹烨民. 动脉粥样硬化抗炎治疗的研究进展［J］. 中国现代医学杂志， 2023， 33（5）： 50-55.
18	WOLF D， LEY K. Immunity and inflammation in atherosclerosis［J］. Circ Res， 2019， 124（2）： 315-327.
19	BÄCK M， YURDAGUL A Jr， TABAS I， et al. Inflammation and its resolution in atherosclerosis： mediators and therapeutic opportunities［J］. Nat Rev Cardiol， 2019， 16（7）： 389-406.
20	李思瑞，冯泽清，吴玉章. C1632通过MAPK和NF-κB抑制巨噬细胞M1型极化［J］. 免疫学杂志， 2022， 38（3）： 185-192.
21	ZHOU X， XU S N， YUAN S T， et al. Multiple functions of autophagy in vascular calcification［J］. Cell Biosci， 2021， 11（1）： 159.
22	BENNETT M R， SINHA S， OWENS G K. Vascular smooth muscle cells in atherosclerosis［J］. Circ Res， 2016， 118（4）： 692-702.
23	MARCOVECCHIO P M， THOMAS G D， MIKULSKI Z， et al. Scavenger receptor CD36 directs nonclassical monocyte patrolling along the endothelium during early atherogenesis［J］. Arterioscler Thromb Vasc Biol， 2017， 37（11）： 2043-2052.
24	DONG X Z， HU H J， FANG Z D， et al. CTRP6 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration［J］. Biomedecine Pharmacother， 2018， 103： 844-850.
25	NEWBY A C， GEORGE S J. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies［J］. Cardiovasc Res， 1993， 27（7）： 1173-1183.
26	ZHANG S G， ZHANG S H， LIANG X， et al. Guanxinping ameliorates atherosclerosis via MAPK/NF-κB signaling pathway in ApoE^-/- mice［J］. Perfusion， 2023， 38（3）： 557-566.
27	ZEBOUDJ L， GIRAUD A， GUYONNET L， et al. Selective EGFR （epidermal growth factor receptor） deletion in myeloid cells limits atherosclerosis-brief report［J］. Arterioscler Thromb Vasc Biol， 2018， 38（1）： 114-119.
28	VLACIL A K， SCHUETT J， RUPPERT V， et al. Deficiency of Nucleotide-binding oligomerization domain-containing proteins （NOD） 1 and 2 reduces atherosclerosis［J］. Basic Res Cardiol， 2020， 115（4）： 47.
29	HANG M， LI F， WANG X， et al. MiR-145 alleviates Hcy-induced VSMCs proliferation， migration， and phenotypic switch through repression of the PI3K/Akt/mTOR pathway［J］. Histochem Cell Biol，2020，153：357-366.
30	李文倩. 齐墩果酸经FGF2/JNK/PON2通路抑制ox-LDL诱导的大鼠血管平滑肌细胞增殖［D］. 青岛：青岛大学， 2018.
31	梁文静. 糖尿病及血管新生因子对动脉粥样硬化斑块不稳定性的影响及作用机制［D］. 济南：山东大学， 2018.
32	LEE J G， KAY E P. NF-κB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in cornea［J］. Invest Ophthalmol Vis Sci， 2012， 53（3）： 1530-1538.
33	朱莹. FGF/FGFR3与非经典NF-κB信号通路的交互作用及其在多发性骨髓瘤细胞增殖中的意义［D］. 重庆：第三军医大学， 2013.

Herb	Ingredient	Name	Representative target
Salvia miltiorrhiza	Miltirone	DS49	MAPK9,ANG,SOD,JUN
	Dan-shexinkum D	DS8	AR,NOS2,PPARG
	Luteolin	DS51	AKT1,EGFR,IL-10,IL-6
	Tanshinone ⅡA	DS25	NCOA1,FOS,MYC
	Cryptotanshinone	DS29	RELA,PTGS2,STAT3
	Prolithospermic acid	DS41	NOS2,PTGS1,ESR1
Pseudo-ginseng	Stigmasterol	SQ4	PTGS2,PLAU
Pseudo-ginseng	Quercetin	SQ5	PLAT,BCN5A,TNF,CXCL8
Panax quinquefolius	Papaverine	XYS2	APOA1,APOE,APOC1
Panax quinquefolius	Daucosterol_qt	XYS5	PGR,NCOA2
Trichosanthes peel	Naphthalene	GLP4	NF-κB1,IL-6
Trichosanthes peel	Methyl Palmitate	GLP3	NPR1,NPR2,NPR3,AR
Hirudo	Cholesterol	SZ4	PPARA,PPARG,PRKCG
	Adenosine	SZ2	DDP4,SRC,MAPK1
	Methyl 14-methylpentadecanoate	SZ11	JAK2,APOE,IDH1
	Methyl 11-methylhexadecanoate	SZ8	CA2,CA1,VDR,FABP4
Polygonum multiflorum	Tetrahydroxytaxadiene	HSW1	ESR1,PGR,VDR
Polygonum multiflorum	Fetidine	HSW2	HTR2A,DRD2
Gastrodia elata	p-Hydroxybenzyl alcohol	TM2	PTGS2,PPARG,IL-1B
	M-Hydroxybenzoic Acid	TM3	PPARG,MAPK9,IL-1B
Drug share ingredient	Ginsenoside rh2	A	BAX,TNF,NF-κBIA,IL-1B
	20-Hexadecanoylingenol	B	APOC2,PRKCA
	Beta-sitosterol	C	PIK3CG,PTGS1,PTGS2
	Gamma-sitosterol	D	NFKB1,WNT4,BAX,AR

Gene	Corresponding protein
AKT1	RAC-alpha serine/threonine-protein kinase
APOB	Apolipoprotein B-100
CASP-1/-3/-9	Caspase-1/-3/-9
CXCL8	Interleukin-8
FOS	Protein c-Fos
HIF1A	Hypoxia-inducible factor 1-alpha
ICAM-1/-2/-3	Intercellular adhesion molecule 1/2/3
IL-6/IL-1β	Interleukin-8
JAK1/2	Tyrosine-protein kinase JAK1
MAPK1	Mitogen-activated protein kinase
MTOR	Threonine-protein kinase mTOR
NFKB1/2	Nuclear factor NF-kappa-B p105 subunit
NOD1/2	Nucleotide-binding oligomerization domain- containing protein 1/2
NOS1/2/3	Nitric oxide synthase
RELA	Nuclear factor kappa B p65
PLAT	Tissue-type plasminogen activator
STAT1/2/3	Signal transducer and activator of transcription
VEGFA	Vascular endothelial growth factor A

Group		Proliferation activity
Blank		1.212±0.129
Ox-LDL (mg·L^-1) 0.012 5		1.489±0.223^*
0.025 0		1.941±0.131^*
0.050 0		2.233±0.094^*
0.100 0		2.418±0.166^*
0.200 0		2.234±0.106^*

Group	Proliferation activity
Blank	0.75±0.06
XBTMF （mg·L^-1） 0.025	0.71±0.05
0.050	0.66±0.07^*
0.100	0.66±0.02^*
0.200	0.67±0.05^*
0.400	0.68±0.03^*
0.800	0.75±0.07

Group	Proliferation activity
Blank	0.57±0.03
Model	0.81±0.05^*
Rosuvastatin	0.63±0.04^△
XBTMF（mg·L^-1 ）
0.025	0.66±0.03^△
0.050	0.57±0.05^△
0.100	0.45±0.03^△#
0.200	0.83±0.05^#
0.400	0.81±0.06^#
0.800	0.80±0.02^#

Network pharmacological analysis and in vitro experimental verification based on anti-atherosclerosis mechanism of Xiaoban Tongmai Formula

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 17

References 33

Related Articles 15

Metrics

Comments

Recommended 10

Group	MCP-1	IL-6	IL-8
Blank	266.80±18.04	36.66±0.23	297.95±18.06
Model	413.36±39.99^**	41.12±2.70^*	373.45±22.37^*
Rosuvastatin	296.06±8.42^△	13.11±4.08^△△	340.03±6.65
XBTMF（mg·L^-1）
0.025	173.63±0.94^△△#	14.49±3.45^△△	333.81±19.97
0.050	103.20±15.34^△△#	11.32±2.95^△△	208.46±10.60^△△#
0.100	36.58±0.07^△△#	9.24±0.87^△△	156.68±4.62^△△#

Group	NF-κB p65 mRNA	FGF2 mRNA
Blank	1.00±0.11	1.00±0.10
Model	1.85±0.22^*	2.35±0.13^*
Rosuvastatin	0.95±0.01^△	1.27±0.07^△
XBTMF（mg·L^-1）
0.025	1.13±0.13^△	2.30±0.08
0.050	0.43±0.02^△#	1.07±0.10^△#
0.100	0.33±0.04^△#	0.53±0.06^△#

Group	NF-κB p65 protein	FGF2 protein
Blank	0.660±0.008	1.88±0.13
Model	1.200±0.002^*	3.83±0.25^*
Rosuvastatin	0.630±0.002^△	1.31±0.05^△
XBTMF（mg·L^-1）
0.025	0.710±0.003^△	2.41±0.11^△#
0.050	0.360±0.001^△#	1.26±0.03^△
0.100	0.250±0.002^△#	0.58±0.03^△#

[1]	Hua CHEN,Na SHA,Ning LIU,Yang LI,Haijun HU. Effect of human bone marrow mesenchymal stem cells on biological behavior of human liposarcoma SW872 cells through YAP [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1000-1008.
[2]	Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015.
[3]	Chaojie GUO,Jiajia ZHANG,Jie ZENG,Huiyu WANG, AIERFATI·Aimaier,Jiang XU. Expressions of PLOD1 in oral squamous cell carcinoma tissue and cells and their significances [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1035-1043.
[4]	Xinchen ZHOU,Shuhan DONG,Zhuo ZHANG,Mingmei SHEN,Xiangjun WANG,Ying LI,Limei LIU. Network pharmacology analysis based on potential mechanism of dandelion-mulberry leaf in treatment of acute myeloid leukemia [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1087-1097.
[5]	Xiaoyu WANG,Bing LI,Guohui LIU. Research progress in application of inflammatory markers in diagnosis and treatment of coronary heart disease [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1173-1181.
[6]	Guoxing YU,Xin ZHANG,Hengwei DU,Bingjie CUI,Na GAO,Cuilan LIU,Jing DU. Effect of urolithin C on proliferation, apoptosis and autophagy of human acute myeloid leukemia HL-60 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 908-916.
[7]	Yingqun NI,Mao YANG,Di YANG,Chenglin GUO,Wenjun ZHU,Yaqin YU,Qin LU,Jinzhi LUO,Chunqin WU,Zhaohui FANG. Screening of key differentially expressed genes involved in osteogenic differentiation of lower limb vascular smooth muscle cells and validation [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 620-627.
[8]	Zijia ZHU,Xia CHEN,Man CUI,Jihong WEN,Ping WANG,Dong SONG. Bioinformatics and molecular docking technology analysis on mechanism of salidroside on key differential genes of triple negative breast cancer [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 759-769.
[9]	Shuang CHEN,Hong LI. Effect of silencing FOXK1 gene on proliferation, migration, and invasion of gastric cancer HGC-27 cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 371-378.
[10]	Linru WANG,Jing ZHANG,Dongchan ZHAO,Jinjun WANG,Wenxian HU. Effect of silencing FOXO1 gene on autophagy and apoptosis of human aortic vascular smooth muscle cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 431-441.
[11]	Huijuan SONG,Zhenhua XU,Dongning HE. Effect of apolipoprotein C1 expression on proliferation and apoptosis of human liver cancer HepG2 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 128-135.
[12]	Yang YU,Dan TIAN,Donghe NI,Duo ZHANG. Network pharmacologry and molecular docking analysis based on mechanism of monk fruit in treatment of diabetic nephropathy [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 161-167.
[13]	Jie ZENG,Xueyan YU,Ting LUO,Jiang XU. Effect of PD-L1 on proliferation, migration, and invasion of human oral squamous carcinoma cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 18-24.
[14]	Aiying CHEN,Jinwen JIANG,Hui ZHANG. Network pharmacology and molecular docking analysis based on mechanism of Huangqin Tang in treatment of colorectal cancer [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 208-220.
[15]	Li LIU,Linsheng HUANG,Yongheng ZHAO,Wenjie CAO,Yongshuai QIAN,Huifan YU,Fei LI. Network pharmacological analysis on Balanophora involucrataHook.f. in treatment of hyperuricemia and its therapeutic effect on hyperuricemia cell model and hyperuricemia model mouse [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 58-70.